Northwestern investigators have demonstrated that fine-tuning DNA interaction strength can improve colloidal crystal engineering to enhance their use in creating an array of functional nanomaterials.
A combination treatment approach using two chemotherapy drugs improved treatment response and progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to a recent clinical trial published in the Journal of Clinical Oncology.
Patients with advanced-stage melanoma who received immunotherapy both before and after surgery had longer event-free survival than patients who received immunotherapy only after surgery, according to a recent clinical trial published in the New England Journal of Medicine.
Combining a new hormone therapy drug with chemotherapy and another hormone therapy increased overall survival in patients with high-volume and both high-risk and low-risk metastatic hormone-sensitive prostate cancer, according to a post hoc analysis published in the Journal of Clinical Oncology.
Northwestern experts weigh in on how ChatGPT has and will continue impact biomedical research, and how artificial intelligence can be used to support the advancement of science and medicine.
Liver transplant recipients who met the criteria for frailty had comparatively worse quality of life after their transplant, according to a new multicenter study published in JAMA Surgery.
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a recent Northwestern Medicine study.
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.
Increased levels of the antibody immunoglobulin A (IgA) are correlated with the manifestation of several diseases and African ancestry, according to findings published in Nature Communications.
Patient-reported outcomes in relapsed or refractory large B-cell lymphoma revealed that receiving CAR T-cell immunotherapy was associated with higher quality of life, according to a recent study.